You have no items in your shopping cart.
Search results for: 'SARS-CoV-2'
98.00%
76.23 kDa (predicted); 101.54 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations T19R, T95I, E156G, 157-158 deletion, L452R, T478K, D614G, P681R) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant AY.4) which emerged in the United Kingdom. Predicted N terminal: Val 16
C-His
100 μg98.00%
76.29 kDa (predicted); 102.30 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations T19R, T95I, G142D, Y145H, E156G, 157-158 deletion, A222V, L452R, T478K, D614G, P681R) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant AY.4.2) which emerged in the United Kingdom. Predicted N terminal: Val 16
C-His
100 μg98.00%
28.64 kDa (predicted); 36.08 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Arg 319
C-His-Avi
20 μg98.00%
134.17 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations T19R, E156G, 157-158 deletion, A222V, L452R, T478K, D614G, P681R, D950N) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Val 16
C-His
100 μg98.00%
46.31 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutations P13L, ERS31-33 deletion, R203K, G204R) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Met
N-His
100 μg98.00%
76.48 kDa (predicted); 99.56 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations A67V, HV69-70 deletion, T95I, G142D, VYY143-145 deletion, N211 deletion, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Val 16
C-His
100 μg98.00%
136.67 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations A67V, HV69-70 deletion, T95I, G142D, VYY143-145 deletion, N211 deletion, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, N856K, A892P, A899P, A942P, Q954H, N969K, L981F, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Val 16
C-His
100 μg98.00%
134.20 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations T19R, V70F, E156G, 157-158 deletion, A222V, K417N, L452R, T478K, D614G, P681R, D950N) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant AY.2) which emerged in the India. Predicted N terminal: Val 16
C-His
100 μg98.00%
76.06 kDa (predicted); 114.84 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations P9L, C136F, 144-145 deletion, R190S, D215G, Y449H, E484K, N501Y, D614G, H655Y, N679K) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.1.2) which emerged in the South Africa. Predicted N terminal: Val 16
C-His
100 μg98.00%
134.14 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations T19R, E156G, 157-158 deletion, L452R, T478K, D614G, P681R, D950N) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant AY.3, AY.4) which emerged in the India. Predicted N terminal: Val 16
C-His
100 μg
